Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2025 Earnings Call Transcript
Operator: Good morning ladies and gentlemen and welcome to the Alnylam Pharmaceuticals Q1 2025 Earnings Conference Call. At this time, all lines are in a listen-only mode.
Alnylam Pharmaceuticals Inc. (ALNY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 74,000,000 | $85,478,880 | -8% | 3.46% | |
| 2. | Antipodes Partners Jacob Mitchell | 159,554 | $43,086,228 | +20% | 1.35% |
| 3. | 25,000 | $6,750,500 | 16.27% | ||
| 4. | 4,100,000 | $4,735,295 | 0.24% | ||
| 5. | Leucadia National Ian Cumming And Joseph Steinberg | 15,347 | $4,143,997 | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.67 | 4 | Director | 36 | 2024-10-17 | Filing | |
| $286.00 | 32 | Director | 32 | 2024-08-29 | Filing | |
| $71.87 | 297,501 | Large Shareholder | 10,554,134 | 2017-05-31 | Filing | |
| $65.35 | 11,500 | Officer | 11,500 | 2017-05-30 | Filing | |
| $37.00 | 27,900 | Director | 27,900 | 2016-10-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $232.86 | 36 | Director | 0 | 2025-04-16 | Filing | |
| $300.00 | 5,445 | Officer | 20,221 | 2025-03-24 | Filing | |
| $285.00 | 4,321 | Officer | 20,221 | 2025-03-21 | Filing | |
| $299.00 | 7,440 | Director | 136 | 2025-03-24 | Filing | |
| $242.93 | 71 | Officer | 13,501 | 2025-03-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,749,623 | $4,522,698,635 | 0.73% | |
| 2. | 15,309,860 | $4,133,968,399 | 0.26% | |
| 3. | 13,056,605 | $3,525,544,482 | 0.06% | |
| 4. | 9,559,382 | $2,581,224,460 | 0.05% | |
| 5. | 7,154,728 | $1,931,903,727 | 0.42% |
News See All
10 Best Growth Stocks to Buy According to Billionaires
The stock market has been on a rollercoaster ride for the past few weeks as the sentiment has quickly shifted from post-election bullishness to being priced in for a slow-down or a recession.
10 Best Long Term Growth Stocks to Buy According to Billionaires
As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, immigration, and global geopolitics, resulting in elevated levels of uncertainty and...
10 Oversold Biotech Stocks to Buy Now
Biotechnology stocks are among the most volatile in the market, primarily due to the high risks associated with their performance.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2024 Earnings Call Transcript February 13, 2025Alnylam Pharmaceuticals, Inc. misses on earnings expectations.
10 Best Performing Biotech Stocks in 2024
The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and government assistance.
10 High Growth Healthcare Stocks to Invest in Now
During lean economic times, investing in healthcare stocks is generally regarded as defensive.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2024 Earnings Call Transcript October 31, 2024Alnylam Pharmaceuticals, Inc. beats earnings expectations.
Not Holding Alnylam Pharmaceuticals (ALNY) Hurt Fidelity Growth Strategies Fund’s Performance
Fidelity Investments, an investment management company, released its “Fidelity Growth Strategies Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Best Aggressive Growth Stocks to Buy According to Hedge Funds
If you're putting money in the stock market, it's more likely than not that growth is the thing that's on your mind.